Thus, exosomal circCCAR1 secreted by HCC cells promotes resistance to anti-PD1 therapy by accelerating CD8 + T-cell dysfunction, and targeting exosomal circCCAR1 may be a potential therapeutic strategy for HCC patients. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.